Global Contraceptive Pills Market - Growth, Trends and Forecasts (2017 - 2022)

The global market for contraceptive pills is estimated to be USD 680 million in the year 2014. This market is expected to reach USD 1.03 billion by the end of 2019. During this period, the market is estimated to grow at a CAGR of 8.72%.

Global Contraceptive Pills Market-Market Dynamics

The report details several driving and restraining factors for the contraceptive pills market. Some of these are discussed below.


Contributing to the growth of the contraceptives market globally is the necessity to avoid unwanted pregnancies and their complications. A high percentage of women who are sexually active do not want to become pregnant. This number is as high as 70% in the USA. The need to avoid unwanted pregnancies, especially in the teenage women, is one of the major drivers for this market.

It is also observed that more than half of the women identify non-contraceptive health benefits, such as treatment for excessive menstrual bleeding, menstrual pain, and acne, as reasons for use. This is also one of the factors contributing to the growth of the market. The other factors helping the growth of the contraceptives market are the increasing incidence of STDs and the rapid increase in population. Government initiatives promoting the use of contraceptives to avoid unnecessary births and the health benefits from using the contraceptives have also been important players in the growth of the market.


Factors such as religious and cultural opposition in certain emerging nations have been restraining the growth of this market. Along with this, the fear of certain side effects and issues such as infertility resulting from the use of contraception have been major setbacks from the market point of view. Issues such as limited access to contraception in the developing and economically backward nations have been another setback to this market. It is estimated that among the global female population, the need for contraceptive prevalence or meeting the needs of family planning is estimated to as high as 16.2%.

The global market for contraceptives pills can be segmented on the basis of the type of contraceptive pills used and on the mode of delivery namely oral, topical and contraceptive injectable.

Geographically, the contraceptive pills hold the worldthird largest market share. The pill is the third most widely used contraceptive method in the world, with nine percent of women aged 15 to 49 who are married or in a union relying on it. The use of the contraceptive pill has the widest geographic distribution compared to any method. However, there is a large population with unmet needs in terms of contraceptive usage. This makes emerging nations hot destinations for the contraceptives market.

Some of the key players in this market are:

Agile Therapeutics

ANI Pharmaceuticals

Bayer Healthcare

Fuji Latex

Johnson & Johnson

Lupin Pharmaceuticals

Merck & Co

Mylan Laboratories


Reckitt Benckiser

The Female Health Company

What the Report Offers

Market definition for global contraceptive pills market mark along with identification of key drivers and restraints for the market.

Market analysis for the global contraceptives pills market, with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An exhaustive understanding of the global contraceptive pills market.

A comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

Wide-ranging information provided about the leading market players and the major strategies adopted by them.

1. Introduction

1.1 Report Description

1.2 Research Methodology

1.3 Major Stakeholders

2. Executive Summary

2.1 Key Findings

2.2 Market Overview

3. Market Overview

3.1 Market Definition

3.1.1 Introduction

3.2 Market Drivers

3.2.1 Product Innovation

3.2.2 Increasing incidence of STD's

3.2.3 Pregnancy prevention

3.2.4 Immediate Health benefits other than birth control

3.2.5 Rise in Government initiatives to prevent unwanted abortions and pregnancies

3.2.6 Rapid increase in global population

3.3 Market Restraints

3.3.1 Fear or experience of side effects

3.3.2 Cultural or Religious opposition

3.3.3 Limited access to contraception

3.3.4 Infertility issues

3.3.5 Economic constraints

3.4 Market opportunities

3.4.1 New product pipelines

3.4.2 Male Contraceptive Drugs

3.5 Porter's Five Force Analysis

3.5.1 Threat of a new entrant

3.5.2 Internal Rivalry

3.5.3 Buyer Bargaining Power

3.5.4 Supplier Bargaining Power

3.5.5 Threat of substitutes

4. Global Market for Contraceptive Pills

4.1 Market Overview

4.2 Market Segmentation

4.3 Market Share Analysis

4.4 Geographical Analysis

4.4.1 North America USA Canada Mexico

4.4.2 Europe UK Germany France Spain Italy Others

4.4.3 Asia-Pacific China India Japan South Korea Australia Others

4.4.4 Rest of the World Brazil Argentina Middle East Africa

5. Competitive Landscape

5.1 Mergers & Acquisitions

5.2 New Product Launches

5.3 Agreements, Collaborations & Partnerships

5.4 Market Chain Analysis

5.5 Price Share Analysis

5.6 Recommendations for New market players

5.7 Recommendations for Existing market players

6. Company Profiles

6.1 Bayer Healthcare

6.1.1 Overview

6.1.2 Major Products and Services

6.1.3 Financials

6.1.4 Recent Developments

6.2 Pfizer

6.2.1 Overview

6.2.2 Major Products and Services

6.2.3 Financials

6.2.4 Recent Developments

6.3 Merck & Co

6.3.1 Overview

6.3.2 Major Products and Services

6.3.3 Financials

6.3.4 Recent Developments

6.4 Teva Pharmaceuticals, Ltd

6.4.1 Overview

6.4.2 Major Products and Services

6.4.3 Financials

6.4.4 Recent Developments

6.5 Agile Therapeutics

6.5.1 Overview

6.5.2 Major Products and Services

6.5.3 Financials

6.5.4 Recent Developments

6.6 Actavis PLC

6.6.1 Overview

6.6.2 Major Products and Services

6.6.3 Financials

6.6.4 Recent Developments

6.7 ANI Pharmaceuticals, Inc.

6.7.1 Overview

6.7.2 Major Products and Services

6.7.3 Financials

6.7.4 Recent Developments

6.8 Church & Dwight, Co. Inc.

6.8.1 Overview

6.8.2 Major Products and Services

6.8.3 Financials

6.8.4 Recent Developments

6.9 Fuji Latex Co., Ltd

6.9.1 Overview

6.9.2 Major Products and Services

6.9.3 Financials

6.9.4 Recent Developments

6.10 Johnson & Johnson, Ltd

6.10.1 Overview

6.10.2 Major Products and Services

6.10.3 Financials

6.10.4 Recent Developments

6.11 Lupin Pharmaceuticals, Ltd

6.11.1 Overview

6.11.2 Major Products and Services

6.11.3 Financials

6.11.4 Recent Developments

6.12 Okamato Industries, Inc.

6.12.1 Overview

6.12.2 Major Products and Services

6.12.3 Financials

6.12.4 Recent Developments

6.13 Reckitt Benckiser Group, PLC

6.13.1 Overview

6.13.2 Major Products and Services

6.13.3 Financials

6.13.4 Recent Developments

6.14 The Female Health Company

6.14.1 Overview

6.14.2 Major Products and Services

6.14.3 Financials

6.14.4 Recent Developments

6.15 Mylan Laboratories

6.15.1 Overview

6.15.2 Major Products and Services

6.15.3 Financials

6.15.4 Recent Developments

7. Appendix

7.1 Abbreviations

7.2 Sources

7.3 Bibliography

7.4 Disclaimer

Content are not available

Choose License Type